Alzheimer’s drug failure deals blow to Eli Lilly
An experimental Alzheimer’s medicine has flunked a large clinical trial, wiping more than $10bn off the market value of its developer Eli Lilly and dealing a significant setback to the hunt for a drug to delay the fatal disease. Investors and analysts had tipped the medicine, known as Solanezumab, or Sola, to be the first drug that could delay dementia in Alzheimer’s patients, after earlier studies appeared […]